†W·-wcwcAvB

†W·j¨vb‡mvcÖv‡Rvj AvBGbGb 30 wgMÖv

উপাদান

†W·-wcwcAvB : cÖwZwU K¨vcmy‡j i‡q‡Q G‡›UwiK †Kv‡UW wc‡jUm wn‡m‡e †W·j¨vb‡mvcÖvRj AvBGbGb 30 wgMÖv|

বিবরণ

†W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) wW‡jBW wiwjR K¨vcmyj, GKwU †cÖvUb cv¤ú BbwnweUi (wcwcAvB), hv M¨vw÷ªK GwmW wbtmi‡Y evuav †`q| †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) n‡"Q j¨vb‡mvcÖvRj (hv R Ges S-GbvbwmIgvi Gi GKwU †i‡mwgK wgkÖb) Gi R-GbvbwmIgvi| †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) Wz‡qj wW‡jBW wiwjR K¨vcmyj wn‡m‡e †me‡bi Rb¨ mieivn Kiv nq| †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) K¨vcmy‡j i‡q‡Q `y'ai‡bi G‡›UwiK †Kv‡UW MÖvby‡qjm& hv‡`i wfbœ wfbœ pH G wbtmiY N‡U|

কার্যপদ্ধতি

†W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) GKwU wcwcAvB hv M¨vw÷ªK c¨vivBUvj †Kv‡l H^+/K^+ ATPase †K evav cÖ`vb K‡i M¨vw÷ªK GwmW wbtmiY cÖwZ‡iva K‡i| †W·j¨vb‡mvcÖvRj †cÖvUb cv‡¤úi Dci wbw`©ófv‡e KvR K‡i GwmW Drcv`‡bi P,ovšÍ avc eÜ K‡i|

ফার্মোকোকাইনেটিক্স

Wz‡qj wW‡jBW wiwjR cÖwµqvq ^Zix †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) †me‡bi ci cøvRgvi NbZ¡ mgq †cÖvdvB‡j `ywU wbw`©ó wbtmiY †`q| cÖ_g wbtmiY †`q †me‡bi 1 †_‡K 2 NÈvi g‡a¨ Ges cieZ©x wbtmiY †`q 4 †_‡K 5 NÈv ci| GKB w`‡b GKvwaK gvÎvq †me‡bi ciI †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) kix‡i Rgv nq bv| †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) †me‡bi ci gvÎv cwieZ©‡bi mv‡_ mv‡_ Cmax Ges AUC cwiewZ©Z nq| †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) `ªæZ wjfv‡ii gva¨‡g †gUv‡evjvBRW n‡q cÖ¯ªve w`‡q kixi †_‡K †ei nq|

নির্দেশনা

- B‡ivwmf B‡mv‡dRvBwUm wbivgq : †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) B‡ivwmf B‡mv‡dRvBwUm Gi mKj †MÖ‡Wi Rb¨ 8 mßvn ch©šÍ e¨eüZ nq|
- my¯´ B‡ivwmf B‡mv‡dRvBwU‡m †gBb‡UB‡bÝ : my¯´ B‡ivwmf B‡mv‡dRvBwUm Ges A¤^j wbivg‡qi Rb¨ †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) G gvÎv I †mebwewa
- wmg‡Uv‡gwUK bb B‡ivwmf M¨v‡÷¨vB‡mv‡dwRqvj wid¬v· †ivM : †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) eyK R¡vjv‡cvov, wmg‡Uv‡gwUK bb B‡ivwmf M¨v‡÷¨vB‡mv‡dwRqvj wid¬v· †iv‡Mi wPwK¡mvq 4 mßvn ch©šÍ e¨eüZ nq|

my¯´ B‡ivwmf B‡mv‡dRvBwUm †gBb‡UB‡bÝ Ges A¤^j wbivgq	30 wgMÖv	cÖwZw`b 1wU
wmg‡Uv‡gwUK bb B‡ivwmf wR.B.Avi.wW.	30 wgMÖv	cÖwZw`b 1wU K‡i 8 mßvn ch©šÍ

মাত্রা ও সেবনবিধি

গুরুত্বপূর্ন সেবন বিধি

†W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) Lvevi Av‡M I c‡i †meb Kiv hvq|
†W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) m¤ú~Y© wM‡j LvIqv DwPZ|
†W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) K¨vcmyj wb¤œ Dcv‡qI †meb Kiv hvqt
- K¨vcmyjwU Lyjyb|
- MÖ¨vby‡qj,‡jv 1wU †Uwej Pvg‡P Qwo‡q w`b|
kxNÖB wM‡j †djyb| MÖvby‡qj,‡jv wPev‡bv DwPZ bq|

মিস্‌ড ডোজ

wbw`©ó †Kvb gvÎv †me‡b wejw¤^Z n‡j `ªæZ mgcwigvb gvÎv †meb Ki‡Z n‡e| hw` cieZ©x gvÎv MÖn‡bi mgq n‡q Av‡m Zvn‡j wb‡`©wkZ gvÎvi †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj)-B MÖnY Ki‡Z n‡e| †Kv‡bv Ae¯´v‡ZB wØ„Y gvÎv GK‡Î MÖnY Kiv hv‡e bv|

গর্ভাবস্থা ও স্তন্যদানকালে ব্যবহার

‡cÖMb¨vÝx K¨vUvMix we|
Mf©ve¯´vq †W·j¨vb‡mvcÖvR‡ji e¨envi m¤¢eZ wbivc`, hw`I m¤ú~Y© SzwK m¤ú‡K© GL‡bv Rvbv hvqwb|
¯Íb¨vbKvix gwnjv‡`i Dci †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) Gi wbqwš¿Z I h‡_ó Z_¨ †bB| G‡¶‡Î mZK©Zvi mv‡_ †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) †meb Kiv DwPZ

শিশুদের ক্ষেত্রে ব্যবহার

12 eQi ev Zvi Kg eq‡mi wkï‡`i †¶‡Î †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) e¨env‡ii ch©vß Ges mywbqwš¿Z Z_¨ cvIqv hvqwb|

বয়স্ক রোগীদের ক্ষেত্রে ব্যবহার

eq¯‹ †ivMx‡`i †¶‡Î †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) e¨env‡i †Kvb gvÎv cwieZ©b Kivi cÖ‡qvRb †bB|
†ibvj B‡¤úqvi‡g›U
†ibvj B‡¤úqviW †ivMx‡`i †¶‡Î †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) e¨env‡i †Kvb gvÎv cwieZ©b Kivi cÖ‡qvRb †bB|
wjfvi B‡¤úqvi‡g›U
gvBì wjfvi B‡¤úqviW †ivMx‡`i †¶‡Î †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) †mebgvÎvq †Kvb cwieZ©b Avm‡e bv|
gWv‡iU wjfvi B‡¤úqvi‡g‡›U m‡e©v"P ^`wbK 30 wgMÖv †W·-wcwcAvB (†W·j¨vb‡mvcÖvRj) MÖnY Kiv hv‡e|

প্রতি নির্দেশনা

†W·j¨vb‡mvcÖvRj Gi †Kvb Dcv`v‡bi cÖwZ ms‡e`bkxj †ivMxi †¶‡Î cÖwZwb‡`©wkZ|

পার্শ্ব-প্রতিক্রিয়া

Wvqwiqv, †c‡U e¨_v, ewg ewg fve, k¦vmZ‡š¿i Dcwifv‡M cÖ`vn, ewg I †c‡U M¨vm|

সতর্কতা

M¨vw÷ªK K¨vÝvi †ivM, K¬mwUªwWqvg wWwdwmwj RwbZ Wvqwiqv, nvo fv½v, nvB‡cvg¨vM‡b‡mwgqv, wg‡_vwUª‡·U Ges †W·j¨vb‡mvcÖvRj GKB m‡½ Gi e¨envi|

অন্যান্য ঔষধের সাথে প্রতিক্রিয়া

AvUvR¨vbvwfi, Iqvi‡dwib, U¨vK‡ivwjgvm, K¬wcW‡MÖj I wg‡_vwUª‡·U D‡jøL‡hvM¨|

অতিমাত্রায় সেবন (ওভারডোজ)

†W·j¨vb‡mvcÖvRj AwZgvÎv e¨env‡ii †Kvb D‡jøL‡hvM¨ Z_¨ †bB| †W·j¨vb‡mvcÖvRj 120 wgMÖv Ges 300

প্রস্তুতকারক ঃ
কেমিষ্ট ল্যাবরেটরীজ লিমিটেড
কলেজ রো, বরিশাল, বাংলাদেশ

ƉEX-PPI

Dexlansoprazole INN 30 mg

Composition

ƉEX-PPI : Each capsule contains Dexlansoprazole INN 30 mg as enteric coated pellets.

Description

ƉEX-PPI (Dexlansoprazole) delayed release capsule is a Proton Pump inhibitor (PPI), that inhibits gastric acid secretion. **ƉEX-PPI** (Dexlansoprazole) is the R-enantiomer of lansoprazole (A racemic moxdure of the R and S enantiomers). **ƉEX-PPI** (Dexlansoprazole) supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. **ƉEX-PPI** (Dexlansoprazole) capsule contains a mixture of two types of enteric coated granules with different pH dependent dissolution profiles.

Mechanism of Action

ƉEX-PPI (Dexlansoprazole) is a PPI that suppresses gastric acid secretion by specific inhibition of the (H^+/K^+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, **ƉEX-PPI** (Dexlansoprazole) blocks the final step of acid production.

Pharmacokinetics

The formulation of **ƉEX-PPI** (Dexlansoprazole) utilizing Dual Delayed Release technology results in plasma concentration time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours. No accumulation of Dexlansoprazole occurs after multiple once daily doses of **ƉEX-PPI** (Dexlansoprazole) 30 mg. After oral administration of **ƉEX-PPI** (Dexlansoprazole) 30 mg to healthy subjects,Cmax and AUC values of Dexlansoprazole increased approximately dose proportionally. Dexlansoprazole is extensively metabolized in the liver and excreted by urine.

Indications

Healing of Erosive Esophagitis: **ƉEX-PPI** (Dexlansoprazole) is indicated for healing of all grades of Erosive Esophagits (EE) for up to 8 weeks. Maintenance of Healed Erosive Esophagitis: **ƉEX-PPI** (Dexlansoprazole) is indicated to maintain healing of EE and relief of heartburn for up to 6 months. Symptomatic Non-Erosive Gastroesophageal Reflux Disease: **ƉEX-PPI** (Dexlansoprazole) is indicated for the treatment of heartburn associated with symptomatic Non-Erosive Gastroesophageal Refux Disease (GERD) for 4 weeks.

Dosage and Administration

ƉEX-PPI (Dexlansoprazole) dosing recommendations

Indication	Recommended Dose	Frequency
Maintenance of Healed EE and relief of heartburn.	30 mg	Once daily
Symptomatic Non-Erosive GERD	30 mg	Once daily for 8 weeks

Important Administration Information

- **ƉEX-PPI** (Dexlansoprazole) can be taken without regard to food or the timing of food.
- **ƉEX-PPI** (Dexlansoprazole) should be swallowed whole.

Alternatively, **ƉEX-PPI** (Dexlansoprazole) capsules can be administered as follows:

-Open capsule
- Sprinkle intact granules on one table spoon
- Swallow immediately. Granules should not be chewed

Missed Dose

If a capsule is missed at its usual time, it should be taken as soon as possible. But if it is too close to the time of the next dose, only the prescribed dose should be taken at the appointed time. A double dose should not be taken.

Pregnant women and Nursing women

Pregnancy Category B Dexlansoprazole is probably safe for use during pregnancy, although the full risks are currently unknown. It is not known whether Dexlansoprazole is excreted in human milk.

Geriatrics

No dosage adjustment is necessary for elderly patients.

Pediatrics

Safety and effectiveness of **ƉEX-PPI** (Dexlansoprazole) in patients below 12 years age have not been established yet.

Renal Impairment

No dosage adjustment is necessary for patients with renal impairment.

Hepatic Impairment

No adjustment of Dexlansoprazole is necessary for patients with mild hepatic impairment. A maximum daily dose of 30 mg for patients with moderate hepatic impairment may be considered.

Contraindication

ƉEX-PPI (Dexlansoprazole) is contraindicated in patients with known hypersensitivity to any component of the formulation.

Side-effects

Diarrhoea, abdominal pain, nausea, upper respiratory tract infection, vomiting & flatulence.

Precautions

Gastric malignancy, Clostridium difficile associated diarrhea, bone fracture, hypomagnesemia,concomitant use of Dexlansoprazole with Methotrexate.

Drug interaction

Alazanavir, Warfarin, Tacrolimus, Clopidogrel & Methotrexate.

Overdose

There have been no reports of significant overdose of Dexlansoprazole. Multiple doses of Dexlansoprazole 120 mg and a single dose of Dexlansoprazole 300 mg did not result in any severe adverse events.

Storage

Store at temperature within 30°C, protected from light and moisture. Keep out of the reach of children.

Packaging

ƉEX-PPI : Each carton contains 30 capsules in Alu-Alu blister pack.

Manufactured by
Chemist Laboratories Ltd.
College Row, Barishal, Bangladesh